Ved Shastri’s Post

𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/gUMXh-7X The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/g8vPGfFa As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry

𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/gUMXh-7X The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/g8vPGfFa As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry

We are excited to announce 199 Biotechnologies as a Tier 2 Sponsor of the 11th Aging Research & Drug Discovery Meeting. 199 Biotechnologies focuses on epigenetic reprogramming, employing unique transcription factors and miRNA to address age-related diseases. The company’s main indications include cancer and neurodegenerative disorders, with additional therapeutic targets in our pipeline. They utilize cell therapy and mRNA-based delivery systems to introduce these reprogramming factors effectively. The approach aims to reverse cellular aging, improve healthspan, and provide innovative solutions for combating complex diseases, leveraging advanced bioengineering and strategic collaborations with leading research institutions. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/g53irYHe #ARDD2024 #DrugDiscovery #AgingResearch

Modiblast Pharma GmbH is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells. Contrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn’t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities. Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte/neutrophil counts. The next step of clinical development is a Phase 1a/2b study which recently has passed BfArM scientific advice. Meet Modiblast Pharma GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Did you know that developing effective drugs is only half the challenge? Because getting them to their site of action is crucial to increase their efficacy and reduce toxicity.      The blood-brain barrier (BBB) is a semi-permeable membrane which regulates the transfer of substances between the circulatory system and the central nervous systems (CNS). It protects the brain from harmful or unwanted substances in the blood, but it can also be a major obstacle for development of CNS drugs as it prevents them from penetrating into the nervous tissue.       This limits efficacy of CNS drugs and many fall by the wayside in clinical development. The BBB remains one of the major challenges in the pharma industry.       Our VECTrans® technology uses receptor-mediated transport (RMT) to deliver drugs or imaging agents to the brain and cancer tissues. The technology is based on the specific design and optimization of ‘molecular vectors’ that, once conjugated to a payload, enable its delivery to target cells in the body. The targeted delivery via RMT avoids invasive administration routes and is believed to be the most effective and safest physiological pathway for the transport of macromolecules across cellular barriers.      Click below to find out more about our technology and its potential to transform treatment of CNS diseases.      https://lnkd.in/dwQK3xCT      #vectors #lifesciences  #biotech #drugdevelopment #cancer #technology #breakingbarriers 

The Hematologic Malignancies Testing Market is on the brink of a massive transformation, projected to soar past $13.509 Billion by 2033!     As the fight against blood cancers intensifies, the demand for advanced diagnostics and personalized treatment options is skyrocketing. Innovations in testing are not just saving lives but also setting new standards in precision medicine. From early detection to targeted therapies, the future of hematologic malignancies testing is brighter than ever.     Are you ready to ride this wave of innovation? Whether you're in biotech, pharma, or healthcare, the growth in this market presents a golden opportunity to make a lasting impact. Let’s lead the charge in revolutionizing blood cancer diagnostics!     Dive into the latest insights and trends that are shaping the future of this dynamic market. Your next big breakthrough could be just around the corner!     Read the entire Blog here:    https://lnkd.in/g45kESew #Hematology #CancerResearch #Biotech #Innovation #Healthcare

Navigating the Complexities and Optimizing Imaging Strategies in GIST Clinical Trials Gastrointestinal Stromal Tumors (GIST) present unique challenges in clinical trials due to their distinct molecular features. Imaging involves multiple modalities and assessment criteria and plays a vital role in monitoring GISTs while enabling the evaluation of diverse imaging findings and post-treatment changes. 🧬 Initially mistaken for leiomyosarcomas, specific mutations in the KIT gene led to GIST's recognition as a separate tumor type. Treatment assessments in GIST trials typically rely on RECIST criteria, focusing on tumor size changes, but mRECIST and Choi criteria offer more comprehensive evaluations by considering additional factors such as enhancement patterns, density, necrotic and cystic changes. PET imaging adds value by detecting metabolically active GISTs and can provide much earlier evidence of response. Strategic application of these criteria can significantly enhance the precision of response evaluations in GIST clinical trials. 📈 Imaging Endpoint’s experts leverage the evolving landscape of imaging techniques for GISTs to enrich understanding of treatment responses beyond anatomical changes, while collaborating closely with sponsors, investigators, and regulators to optimize trial design. As two of our renowned experts Dr. Ron Korn (CMO) and Dr. Manish Sharma (CSO) at Imaging Endpoints, concur: "In GIST drug development it is critical to balance the exploratory nature of early-phase trials with the regulatory rigor of late-phase trials and, to design clinical trials that connect the two effectively." 💡 Strategic application of these imaging criteria can significantly improve the precision of response evaluations in GIST clinical trials. Please reach out to our experienced team https://hubs.li/Q02JxYBf0 for tailoring imaging solutions to support GIST clinical trials effectively. #ImagingEndpoints #MedicalImaging #ClinicalTrials #AdvancedImaging #OncologyResearch #GIST

IV-formulated RNA Restoring Loss of Function of PGC1a and STMN2 in ALS Neurodegeneration. A Significant IV-formulated RNA Weapon in ALS Emerges. Join us at #BIO24 where we're leveraging the power of our proprietary IV—and SC-formulated RNA delivery platform with unprecedented precision to deliver therapeutic agents directly to the CNS, reaching #astrocytes, #microglia, and #neurons with unmatched efficiency. Our ALS target regulates PGC1a and STMN2, which are vital in mitochondrial dynamics and axonal integrity. Dysregulation of these pathways is a cornerstone of ALS pathology, leading to neurodegeneration, inflammation, and cognitive deficits. Further highlights: - Imagine showcasing dramatic improvements in neuromuscular function, evidenced by enhanced CMAP latencies and amplitudes – key indicators of neuromuscular health. Imagine the potential of BMD-001s in halting ALS progression and dramatically improving patients' lives. - With a significant reduction in NfL levels in the CSF, a promising biomarker of neurodegeneration, BMD-001s stands as a testament to our commitment to transforming patient lives. With our new external feasibility study partners, RNAi therapeutics is transforming the future of neurodegenerative disease treatment. #ALS, #RNAiTherapeutics, #Biorchestra, #Neurodegeneration, James Sabry, Roche, Felix Schumacher, The ALS Association, Manish Raisinghani, Daniel Roth, Annette Bak Asceneuron SA, Al Roker, Ferring Pharmaceuticals, Christian Mueller, Sanofi, Francisco Córdoba, Novartis, Juergen Reess, Amylyx Pharmaceuticals, Hans-Juergen Woerle, Servier, UCB, Pfizer, Paul Hudson, Wellington Management, John C. Reed, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pierre Fabre Group, CSL, Brendan Nagle, Wells Fargo Corporate & Investment Banking, Murphy Gallagher, Leerink Partners LLC, Research Division, Leerink Partners, David Soria, Jefferies, n-Lorem Foundation, Endpoints News, STAT, Boston Globe Technology Branden JH (jin-hyeob) RYU, IL-SANG YOON, Fierce Biotech. Photo: Tennessee Titans legend Tim Shaw.

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

𝑷𝒐𝒔𝒆𝒊𝒅𝒂 𝑻𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄𝒔 𝑺𝒆𝒄𝒖𝒓𝒆𝒔 $15𝑴 𝑴𝒊𝒍𝒆𝒔𝒕𝒐𝒏𝒆 𝒘𝒊𝒕𝒉 𝑵𝒆𝒘 𝑫𝒖𝒂𝒍 𝑪𝑨𝑹-𝑻 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 𝑵𝒐𝒎𝒊𝒏𝒂𝒕𝒊𝒐𝒏 𝒊𝒏 𝑹𝒐𝒄𝒉𝒆 𝑪𝒐𝒍𝒍𝒂𝒃𝒐𝒓𝒂𝒕𝒊𝒐𝒏! Poseida Therapeutics, Inc. the clinical-stage leader in allogeneic cell therapy and genetic medicines has just nominated a new development candidate in its collaboration with Roche. This exciting milestone has triggered a $15M payment from Roche to Poseida. 💸 The new candidate? An allogeneic, dual CAR-T therapy targeting antigens in hematologic malignancies, including multiple myeloma. Poseida’s non-viral, transposon-based DNA delivery system allows for the insertion of two full-length chimeric antigen receptors (CARs) into T stem cell memory cells (TSCM), bringing us one step closer to transforming treatments for cancer and rare diseases. 💪🔬 https://lnkd.in/eUMv_Nxm Poseida Therapeutics is hiring for a Senior Vice President, Business Development (San Diego, CA Hybrid) https://lnkd.in/eED85yu4 #CellTherapy #GeneticMedicines #Immunotherapy #Biotech #CancerTreatment #AllogeneicTherapies #MultipleMyeloma